# Rivia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rivia

- Industry: Software
- Headquarters: Zurich, Switzerland
- Website: www.rivia.com/
- Total disclosed funding: $18M
- Latest round: Series A (Mar 18, 2026)
- Investors on record: 5

## About

Based in Zurich, Switzerland, and founded in 2022 by CEO Erik Scalfaro, and CTO Tiago Kieliger, Rivia SA, a.k.a. Rivia operates as a software company that focuses on developing an artificial intelligence (AI)-based analytics and data infrastructure that helps therapeutic innovators manage clinical trial data. In March 2026, Rivia SA raised EUR 13 million in series A funding led by new investor Earlybird, with participation Defiant, Speedinvest, Amino Collective, and Nina Capital also participated in the round.

The company provides infrastructure and an AP-powered platform that allows biotechnology companies to simplify clinical trial data acquisition and understanding through interactive analytics and AI-driven data insights. In addition, the platform’s self-service analytics allow users to visualize data and build advanced analytics independently. Rivia also offers a trial data engine that harmonizes data from various sources, supporting the creation of accurate visit schedules and hypothesis testing.

The company plans to use its proceeds from March 2026 funding to hire staff, improve its clinical trial data engine, and support expansion into the U.S. market.

## Funding rounds

- Series A, Mar 18, 2026, $15M — Earlybird, Speedinvest, Nina Capital, Amino Collective, Defiant
- Seed, Jun 12, 2024, $3.2M — Speedinvest, Nina Capital, Amino Collective

## Investors

- Speedinvest (https://capitalatlas.ai/funds/speedinvest) — Seed, Series A
- Nina Capital (https://capitalatlas.ai/funds/nina-capital) — Seed, Series A
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Seed, Series A
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series A
- Defiant (https://capitalatlas.ai/funds/defiant) — Series A